FILO (Field Interaction Ligand Optimization): A simplex strategy for searching the optimal ligand interaction field in drug design
暂无分享,去创建一个
[1] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.
[2] M. Murcko,et al. Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .
[3] D. Walters,et al. Genetically evolved receptor models: a computational approach to construction of receptor models. , 1994, Journal of medicinal chemistry.
[4] C. B. Lucasius,et al. Understanding and using genetic algorithms Part 2. Representation, configuration and hybridization , 1994 .
[5] Dale J. Kempf,et al. Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .
[6] A. Doweyko,et al. Three-dimensional pharmacophores from binding data. , 1994, Journal of medicinal chemistry.
[7] D. Rogers,et al. Receptor surface models. 2. Application to quantitative structure-activity relationships studies. , 1995, Journal of medicinal chemistry.
[8] M. Hahn. Receptor surface models. 1. Definition and construction. , 1995, Journal of medicinal chemistry.
[9] James P. Snyder,et al. Pseudoreceptor Modeling: The Construction of Three-Dimensional Receptor Surrogates , 1995 .
[10] G. Cruciani,et al. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .
[11] A. Vedani,et al. Pseudo-receptor modeling: a new concept for the three-dimensional construction of receptor binding sites. , 1993, Journal of receptor research.
[12] R. DesJarlais,et al. A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor. , 1995, Journal of medicinal chemistry.
[13] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[14] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[15] A M Hassell,et al. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. , 1992, Biochemistry.
[16] P Murray-Rust,et al. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease. , 1994, Biochemistry.
[17] R. DesJarlais,et al. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis. , 1993, Biochemistry.
[18] M Pastor,et al. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.
[19] Gerd Folkers,et al. PrGen: Pseudoreceptor Modeling Using Receptor‐mediated Ligand Alignment and Pharmacophore Equilibration , 1998 .